Every 424B that Bicara Therapeutics Inc. (BCAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics is offering 7,175,000 shares of common stock and pre-funded warrants to purchase up to 2,200,000 shares in a registered offering at a public offering price of $16.00 per share (pre-funded warrants priced at $15.9999). The company expects net proceeds to be approximately $140.7 million before expenses, and has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares.
Proceeds are intended to support regulatory filing and potential U.S. commercial launch for ficerafusp alfa, accelerate development in 1L R/M HPV-negative HNSCC including a less frequent dosing schedule, fund manufacturing and early signal-finding, and for general corporate purposes. As of December 31, 2025, the company reported approximately $414.8 million of cash, cash equivalents and investments (unaudited, subject to year-end close).
Bicara Therapeutics is offering $150,000,000 of its common stock, subject to completion and the underwriters' 30-day option to purchase up to an additional $22,500,000 of shares.
The prospectus supplement states a reference market price of $16.40 per share as of February 23, 2026, and reports 54,612,477 shares outstanding as of September 30, 2025. As of December 31, 2025, Bicara reported approximately $414.8 million of cash, cash equivalents and investments.
Proceeds are intended to fund regulatory and commercial readiness and continued development and manufacturing of ficerafusp alfa, including Phase 2/3 and dosing-schedule work, and for general corporate purposes; the offering economics and net proceeds per share are shown in the prospectus supplement.
Bicara Therapeutics Inc. is launching an at-the-market offering of up to $150,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on The Nasdaq Global Market under the symbol BCAX, in negotiated transactions or other methods deemed to be at-the-market offerings, with TD Cowen earning a commission of up to 3.0% of gross proceeds.
Bicara is a clinical-stage biopharmaceutical company focused on bifunctional antibodies for solid tumors. Its lead program, ficerafusp alfa, is in a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma, following Phase 1/1b data showing a 54% objective response rate and 21.3‑month median overall survival in an efficacy-evaluable HPV‑negative population. Net proceeds are expected to support research and clinical development, commercialization preparation, expansion of R&D programs, and general corporate purposes.